Financial reports
10-K
2024 FY
Annual report
25 Feb 25
10-Q
2024 Q3
Quarterly report
5 Nov 24
10-Q
2024 Q2
Quarterly report
6 Aug 24
10-Q
2024 Q1
Quarterly report
7 May 24
ARS
2023 FY
Annual report to shareholders
19 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
Current reports
8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
25 Feb 25
8-K
Results of Operations and Financial Condition
13 Jan 25
8-K
Regulation FD Disclosure
9 Dec 24
8-K
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
6 Dec 24
8-K
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
4 Dec 24
8-K
Initial Results from BEACON Phase 1/2 Clinical Trial Demonstrate Potential for Differentiation of Base Editing and BEAM-101
5 Nov 24
8-K
Regulation FD Disclosure
5 Nov 24
8-K
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
5 Nov 24
8-K
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
6 Aug 24
8-K
Beam Therapeutics Announces Transition of Chief Financial Officer
15 Jul 24
Registration and prospectus
S-8
Registration of securities for employees
25 Feb 25
S-3ASR
Automatic shelf registration
27 Feb 24
S-8
Registration of securities for employees
27 Feb 24
424B5
Prospectus supplement for primary offering
10 May 23
S-8
Registration of securities for employees
28 Feb 23
S-8
Registration of securities for employees
28 Feb 22
424B5
Prospectus supplement for primary offering
7 Jul 21
S-3ASR
Automatic shelf registration
10 Jun 21
424B5
Prospectus supplement for primary offering
1 Apr 21
424B7
Prospectus with selling stockholder info
1 Apr 21
Proxies
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
Other
UPLOAD
Letter from SEC
12 Oct 23
CORRESP
Correspondence with SEC
20 Sep 23
UPLOAD
Letter from SEC
22 Aug 23
CORRESP
Correspondence with SEC
9 Aug 23
UPLOAD
Letter from SEC
20 Jul 23
EFFECT
Notice of effectiveness
1 Oct 20
CORRESP
Correspondence with SEC
28 Sep 20
CORRESP
Correspondence with SEC
28 Sep 20
UPLOAD
Letter from SEC
23 Sep 20
EFFECT
Notice of effectiveness
6 Feb 20
Ownership
4
Bethany J Cavanagh
20 Feb 25
4
Christine Bellon
19 Feb 25
SC 13G/A
ARCH Venture Fund IX, L.P.
14 Feb 25
144
Notice of proposed sale of securities
14 Feb 25
SC 13G/A
FMR LLC
12 Feb 25
SC 13G/A
Farallon Capital Partners, L.P.
5 Feb 25
4
Christine Bellon
3 Feb 25
4
Giuseppe Ciaramella
3 Feb 25
4
Amy Simon
3 Feb 25
4
John M. Evans
3 Feb 25